Targeting IgE Antibodies for Allergy Treatment (P43029)

Target Name: Immunoglobulin E (IgE)

NCBI ID: P43029

Immunoglobulin E (IgE)

Other Name(s): None

Targeting IgE Antibodies for Allergy Treatment

Immunoglobulin E (IgE) is a type of antibody that plays a crucial role in the immune response. It is one of the five classes of antibodies produced by B cells, along with IgA, IgD, IgG, IgM, and IgV. IgE is the least abundant of these five classes of antibodies.

IgE is involved in the rapid and immediate response of the immune system to an allergen. When a person is exposed to an allergen, their body produces IgE antibodies, which are released from the surface of the mast cells and basophiles. These antibodies bind to the allergens and cause them to become inflamed, leading to symptoms such as itching, swelling, and inflammation.

One of the major challenges preventing in the treatment of allergies is the difficulty in predicting and the onset of an allergic reaction. This is because the symptoms of an allergic reaction are often similar to those of other medical conditions, making it difficult to diagnose the cause.

The development of new treatments for allergies has been a major area of 鈥嬧?媟esearch in recent years. One potential approach to treating allergies is to target the production of IgE antibodies. This could be done by identifying a drug or biomarker that can inhibit the production of IgE antibodies, or by using a drug that encourages the body to produce less IgE.

One potential drug target for IgE is the protein called Fc蔚RI. This protein is a key receptor on the surface of mast cells and basophiles, and is involved in the production of IgE antibodies. blockade of Fc蔚RI has been shown to be an effective treatment for allergies , both in human and animal models.

Another potential drug target for IgE is the molecule called determinant. This molecule is involved in the production of IgE antibodies, and has been shown to be a potential target for new treatments for allergies.

IgE antibodies have been shown to be involved in a number of allergic reactions, including pollen allergies, food allergies, and asthma. In addition, IgE antibodies have also been shown to play a role in the development of atopic dermatitis, a common form of skin Asthma.

In addition to their role in allergies, IgE antibodies have also been shown to be involved in the immune response in general. They have been shown to play a role in the regulation of inflammation, and have been shown to interact with other immune molecules such as T cells and NK cells.

Overall, the development of new treatments for allergies has been a major area of 鈥嬧?媟esearch in recent years, and the potential of targeting the production of IgE antibodies is an exciting area of 鈥嬧?媠tudy. Further research is needed to determine the most effective and safe methods of treating allergies by targeting the production of IgE antibodies.

Protein Name: Immunoglobulin E (IgE)

The "Immunoglobulin E (IgE) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Immunoglobulin E (IgE) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets